Patients taking GLP-1 drugs, including popular medications like Ozempic and Wegovy, have filed lawsuits alleging the pharmaceutical companies failed to adequately warn about serious health risks. Among the reported complications are vision loss from optic neuropathy, pancreatitis, and gallstone-related conditions. The legal cases center on whether these medications directly caused the harm or merely coincided with it.
An analysis of FDA adverse event reports revealed more than 1,000 submissions describing optic neuropathy linked to GLP-1 drugs since 2024, along with nearly 1,928 reports of pancreatitis. While these represent a small fraction of approximately 190,000 total reports—most involving minor gastrointestinal side effects—they underscore concerns among legal representatives pushing for updated warning labels. Lead litigation attorney Jonathan Orent contends that manufacturers should revise warnings for doctors and patients similar to actions already taken in Europe, even if serious conditions occur rarely.
Pharmaceutical makers maintain that serious adverse events are uncommon in clinical trials. Novo Nordisk, producer of Ozempic, and Eli Lilly, maker of Mounjaro and Zepbound, have stated they will defend against claims and continue monitoring safety data submitted to regulators. The FDA indicated it is conducting its own study to evaluate the risks of optic neuropathy and will determine whether regulatory action is warranted upon completion.
Medical experts note that establishing direct causation presents significant challenges. Obesity and diabetes themselves increase risks for various health complications, making it difficult to isolate whether reported problems stem from the medications or underlying conditions. Some physicians report not submitting adverse event reports when uncertain about causation, even when timing appears suspicious, contributing to gaps in the safety surveillance system that could delay identification of genuine drug-related risks.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI